white blood cell count, 11 × 10 9 /L; D-dimer, 24,360 μg/L. Other biomarkers were normal.
Anticoagulation therapy with low-molecular-weight heparin (LMWH) was administered (4100 U i.h. q12h). Although the clinical diagnosis was lung tumor, anticoagulation treatment was stopped 12 h before pulmonary puncture biopsy. The pathological diagnosis confirmed the presence of an adenocarcinoma; the immunohistochemical results were positive for both thyroid transcription factor-1 and Ki-67 and negative for both p63 and wild-type epidermal growth factor receptor (EGFR), while the ALK was positive with ICH/VANTANA [ Figure 1d ]. Crizotinib was used as an initial therapy (250 mg p.o. bid), combined with the anticoagulation treatment with LMWH.
After 2 months of therapy, CT demonstrated that the thrombi in the right pulmonary artery and superior vena cava were notably reduced. According to the guidelines, the LMWH was used for 3 months; the index of the coagulation function returned to normal, and LMWH was replaced by warfarin (3 mg p.o. qd). One year later, the CT angiography revealed that the thrombi in the right pulmonary artery and superior vena cava had completely disappeared [ Figure 1e ], and the lesion was smaller than before. The warfarin treatment was stopped after one and half years, and no thrombosis-related events have occurred to date. Evaluation of crizotinib as a first-line therapy showed a partial response and disappearance of intracranial lesions. The duration of progression-free survival was 23 months. In September 2016, the intracranial metastasis progressed and was treated with a gamma knife. The patient was on consolidation therapy with oral crizotinib and remained stable until October 18, 2017, during the follow-up period [ Figure 1f ].
Patients with lung cancer are at a particularly high risk for VTE when compared to patients with other tumor types and have a worse prognosis. [2] The current article suggests that a K-ras gene mutation was involved in the pathophysiology of tumor-associated thrombosis; [3] Lee et al. [4] suggested that EGFR mutations and ALK rearrangements were not associated with VTE development. To treat the cancer-associated thrombosis, the favored option is LMWH.
[5] The therapy using crizotinib was effective for the patient and led to a satisfactory quality of life and prolonged survival time. This case indicates the possibility that targeted therapy for adenocarcinoma-driven genes combined with anticoagulant therapy can be one of the protocols to improve the prognosis of advanced lung-cancer patients with thromboses.
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